1
项与 PD-1 knock out CD19 CAR-T (Third Military Medical University) 相关的临床试验CD19 Chimeric Antigen Receptor (CAR) and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma
The purpose of this study is to evaluate the safety, efficacy and blood kinetics of autologous T cells genetically modified to express CD19 Chimeric Antigen Receptor and PD-1 knockout engineered T cells in patients with relapsed or refractory B-Cell Non-Hodgkin Lymphoma and Leukaemia.
100 项与 PD-1 knock out CD19 CAR-T (Third Military Medical University) 相关的临床结果
100 项与 PD-1 knock out CD19 CAR-T (Third Military Medical University) 相关的转化医学
100 项与 PD-1 knock out CD19 CAR-T (Third Military Medical University) 相关的专利(医药)
100 项与 PD-1 knock out CD19 CAR-T (Third Military Medical University) 相关的药物交易